Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627) Article

cited authors

  • Lassman, Andrew B; Pugh, Stephanie L; Gilbert, Mark R; Aldape, Kenneth D; Geinoz, Sandrine; Beumer, Jan H; Christner, Susan M; Komaki, Ritsuko; DeAngelis, Lisa M; Gaur, Rakesh; Youssef, Emad; Wagner, Henry; Won, Minhee; Mehta, Minesh P

fiu authors

publication date

  • July 1, 2015

keywords

  • AGENT
  • BEVACIZUMAB
  • Clinical Neurology
  • DETERMINANTS
  • ERLOTINIB
  • GLIOMA PATIENTS
  • GROWTH-FACTOR RECEPTOR
  • II TRIAL
  • IMATINIB
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • PROGRESSION-FREE SURVIVAL
  • Science & Technology
  • TEMOZOLOMIDE
  • chemotherapy
  • dasatinib
  • glioblastoma
  • phase II
  • tyrosine kinase inhibitor

Digital Object Identifier (DOI)

start page

  • 992

end page

  • 998

volume

  • 17

issue

  • 7